Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 27, 2009

La Jolla Institute to Test IVT’s Delivery Platform with Infectious Disease Candidates

  • ImmunoVaccine Technologies (IVT) signed an agreement with the La Jolla Institute for Allergy & Immunology to test the application of its DepoVax™ vaccine delivery system for influenza and arenavirus vaccines.

    The institute’s epitope-based vaccines are in preclinical research. The goal is that using DepoVax, only one vaccine dose will be required for protective immunity and that a strong cellular and humoral response is achieved.

    DepoVax uses liposomes to encapsulate a target antigen and adjuvant. The vaccine formulation also relies on a hydrophobic oil carrier. The result is a depot effect that enhances vaccine induced cell-mediated and humoral immunity, according to IVT.

Related content

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.